Therefore we may not only hypothesize that the precision medicine approach (employing the MTNR1B rs10830963 gene variant) in predicting the AIT need in a narrow subpopulation of patients already diagnosed with GDM might result in better and earlier identification of patients who would require antenatal insulin therapy (Firneisz et al., 2018), but also—consistently with the findings of the maternal GWAS on neonatal birthweight (Beaumont et al., 2018)—we may potentially expect the reduction of complications (e.g., macrosomia/LGA rate). Here, MTNR1B is linked to gestational diabetes.